Study Shows Safety and Efficacy of Anti-PCSK9 Antibodies in Lowering LDL Cholesterol

A study published in BMC Medicine found that the anti-PCSK9 antibodies Repatha® (evolocumab) and Praluent® (alirocumab) reduced the LDL (bad) cholesterol level by over 50 percent, increased the HDL (good) cholesterol level, and resulted in favorable changes in other lipids. As some patients cannot tolerate statins, there is a need for alternative treatments that lower LDL cholesterol, a major cause of heart disease. Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association.American Heart Association

Read moreRead more